


Landiolol hydrochloride

Cat. No.:	HY-100607A		
CAS No.:	144481-98-1		
Molecular Formula:	C ₂₅ H ₄₀ ClN ₃ O ₈		
Molecular Weight:	546.05		
Target:	Adrenergic Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (457.83 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.8313 mL	9.1567 mL	18.3133 mL
		5 mM		0.3663 mL	1.8313 mL	3.6627 mL
		10 mM		0.1831 mL	0.9157 mL	1.8313 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.81 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (3.81 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.81 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Landiolol hydrochloride (ONO1101 hydrochloride) is a highly beta1 selective ultra-short acting beta -blocker (β1/β2 selectivity = 255:1, a half-life of 4 min)□ acts as an adrenoceptor antagonist ^[1] .
IC ₅₀ & Target	beta-adrenergic receptor ^[1]

REFERENCES

- [1]. Atarashi H, et al. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther. 2000 Aug;68(2):143-50.
- [2]. Okajima M, et al. Landiolol, an ultra-short-acting β 1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med. 2015 Aug 4;4(3):251-7.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA